Vestibular Migraine: What's the Impact?

A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.

Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.

Plasma p-tau217 levels helped estimate 5- and 10-year cognitive impairment risk in older adults without memory or thinking symptoms.

FDA cleared C2N’s PrecivityAD2 blood test to aid Alzheimer disease evaluation in symptomatic adults aged 40 years and older.

A Swedish observational study linked NOAC use to slower cognitive decline in individuals with atrial fibrillation and Alzheimer disease.

The FDA approved oveporexton for narcolepsy type 1 in adults, marking the first orexin receptor agonist targeting the underlying biological cause of narcolepsy.